Overview

View the Digital Invitation (PDF). Agenda Items Include:

• Highlight Exact Sciences portfolio of genomic and genetic tests that can help inform personalized treatment decisions
• Introduce the Riskguard™ & Oncotype DX Breast Recurrence Score® tests
• Discuss the utility of testing with both the Oncotype DX® and Riskguard™ tests

Faculty:

• Jennifer M Racz, MD, MBA, FRCSC
  Director, Medical Affairs, Oncology
  Exact Sciences
• Brandie Heald Leach, MS, CGC
  Senior Director, Medical Affairs, Hereditary Cancer
  Exact Sciences

Overview

As genetic counseling is recommended for an increasing number of patients with cancer, institutions are looking for new strategies to meet this growing demand. By developing efficient genetic counseling and testing service delivery models, more patients may be able to access crucial testing and targeted cancer treatment.

Hear directly from a genetic counselor at a community health system and a genetic counselor at an academic medical center as they share examples of alternative service delivery models, challenges they faced during the implementation of these workflows, and their impact on expanding access to genetic testing for appropriate patients.

Key Topics Include:

• Strategies for accessible education in the pretest setting
• Frameworks to integrate patients, physicians, nurse navigators, and testing coordinators into the genetic counseling process
• Workflows to get genetic testing results quickly and streamline quality care

You can find this important roundtable discussion HERE.

Overview

As technology advances, surgeons need to develop tools to assess the value of new devices and initiatives in patient care. Surgeons will also need to understand the processes by which their institutions evaluate new technology for integration into the system.

Presented by:

• Freya R. Schnabel, MD
  Professor, Department of Surgery at NYU Grossman School of Medicine
  Director of Breast Surgery
  NYU Langone Health
  New York, NY

Overview

In this informative webinar, participants will learn more about:

• Early Detection & Intervention for Subclinical Lymphedema:
  Why It's Important for Our Patients
• Clinical Practice Guidelines & PREVENT Trial Analysis Updates:
  Evidence-Based Insights Supporting Early Detection of Lymphedema
• Operationalizing a Lymphedema Surveillance Program:
  Best Practices for Implementation & Patient Compliance

Overview

Join Breast Surgical Oncologists Dr. Rachel Kaczynski and Dr. Amani Jambhekar, as they share their journey of establishing and building their practices in two different locations, each facing different challenges. Discover how they justified and acquired the KUBTEC MOZART 3D Specimen Radiography System, how it has impacted their practice, and how they present their use of advanced technology to the wider world.

Presenters:

• Rachel E. Kaczynski, DO, FACOS
  Surgical Oncologist, Texas Breast Specialists,
  San Antonio, Texas
• Amani Jambhekar MD, MBA
  Medical Director of Surgical Breast Oncology, CHRISTUS St. Vincent Regional Cancer Center,
  Santa Fe, NM

Overview

This session will educate the audience on how to incorporate genetic and genomic testing insights into clinical practice in order to guide personalized and preventative care and optimize surgical decision making for patients.

Presenters:

• David Weintritt, MD, FACS
  Breast Cancer Surgeon at Virginia Cancer Specialists
• Laura Brzeskiewicz, MS, CGC
  Manager, Medical Science Liaisons at Myriad Genetics

Overview

In Part 2 of our 3-Part series exploring the comprehensive genetics and genomics landscape in breast cancer, we'll dive into Risk Assessment and High-Risk Management. Come along as we explore strategies and tests to assess breast cancer risk and tools for implementing a high-risk breast program in your practice. Let's identify patients together who are at high risk for breast cancer so we can #BeatBreastCancer.

Overview

Join Eric Manahan, MD, MBA, FACS, a leading expert in general and breast surgery, as he shares insights on trending topics in genetic testing for breast cancer. In this webinar, Dr. Manahan covers the importance and underutilization of genetic testing in breast cancer, disparities in genetic testing, unlocking the potential of tumor genomics, exciting research opportunities, and much more. Don't miss out — register today to secure your spot and gain valuable insights on how to elevate your approach to patient care.

Overview

Join us as we take a dive deep into how tumor-informed molecular residual disease (MRD) testing is being integrated into clinical practice today as a valuable tool to help guide treatment decisions for patients with breast cancer. Our expert panel will review the various applications of tumor-informed ctDNA assessment in the neoadjuvant, adjuvant and surveillance settings.

Presenters:

• Angel Rodriguez, MD
  Medical Oncologist, Breast Medical Director
  Natera
• Erica Giblin, MD
  Surgeon, Breast Cancer Specialistr
  Ascension St. Vincent

Overview

As an elite surgeon, you work so hard to do what’s best for your patients and achieve better outcomes, but you can’t see what you need to see in the operating room. Standard technologies lack the resolution to visualize microscopic features associated with early-stage disease in the margins.

Perimeter’s Optical Coherence Tomography (OCT), a category first technology, delivers ultra-high-resolution margin visualization, giving surgeons the ability to gain real-time clarity on margin status. The S-Series OCT offers 10x the resolution of X-ray and ultrasound at 2mm imaging depth, making it a suitable tool for imaging difficult-to-detect disease at the cellular level.

In this webinar, breast surgeons will discuss how OCT helps them control their outcomes and close with confidence.

Why Attend?

• Learn about how OCT provides surgeons with clarity and confidence in the OR
• Hear breast surgeons review cases with OCT technology
• Ask your questions during a live Q&A

Speakers:

• Amani Jambhekar, MD, MBA, FACS
  CHRISTUS St. Vincent
• Jennifer Titensor, MD,
  Utah Surgical Associates
• Catherine A. Ronaghan, MD, FACS
  St. Joseph’s/Candler

Overview

Discover the latest insights from a peer-reviewed study conducted by physicians at MD Anderson and UT Health Houston. This webinar will delve into the critical issue of reoperations in BCS, exploring the associated costs, complications, and profound impact on patients and healthcare systems. This webinar presents a unique opportunity to hear from Dr. Nina Tamirisa, contributing author in the MD Anderson and UT Health study, and Dr. Ted James, as they highlight:

• Trends in Reoperation Rates: Understand the current statistics and trends in reoperation rates following BCS.
• Implications for Patients and Healthcare Systems: Learn about the physical, emotional, and financial burdens reoperations place on patients and the broader healthcare system.
• Strategies to Reduce Reoperations: Gain insights into practices aimed at reducing reoperation rates.
• Live Q&A: Ask your questions to leading experts in the field.

Faculty:

• Nina Tamirisa, MD
  Breast Surgical Oncologist,
  MD Anderson Cancer Center
• Ted James, MD, MHCM, FACS
  Chief of Breast Surgical Oncology,
  Beth Israel Deaconess Medical Center

Overview

• Evaluate latest evidence regarding breast cancer gene mutations in the DNA damage repair (DDR) pathway (eg, BRCA, PALB2, ATM) and their implications on therapeutic and surgical decision-making
• Analyze recent breast cancer genetic testing guideline recommendations and the role of various members of the multidisciplinary team, including surgeons, advanced practice providers, genetic counselors, patient navigators, pharmacists, and nurses in optimizing genetic testing processes for eligible patients in the newly diagnosed breast cancer setting
• Individualize breast cancer treatment selection for DDR-mutated, early-stage and metastatic breast cancers based on the latest safety and efficacy trial data, guideline recommendations, and genetic testing results
• Employ multidisciplinary care coordination models as a means to effectively integrate genetic testing into clinical practice, including considerations for pre- and post-test counseling and informed consent, to optimize breast cancer management and overall outcomes

Overview

This lecture will focus on all types of breast localization, from wire to wire-free options and how each have the potential to increase patient comfort and surgery scheduling flexibility.

Speaker:

• Steven Cai, MD, FACS

CME Information

World Class CME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians and designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. This activity is supported by an unrestricted educational grant from Hologic, Inc.

Overview

During this program, a multidisciplinary panel of experts will discuss the role and importance of surgeons in genetic testing in early breast cancer. Topics will include key characteristics and unmet needs of patients with germline BRCA mutations (gBRCAm), collaborating with the multidisciplinary team to integrate genetic testing in practice, genetic counseling considerations and how gBRCAm testing may inform clinical decisions. View prescribing information.

Program Objectives:

• Discuss the need for individualized care plans for patients with gBRCAm breast cancer due to differences in underlying tumor biology vs non-gBRCAm patients
• Discuss the surgical and treatment implications for patients with gBRCAm eBC
• Explore the role and importance of surgeons within the BRCA testing pathway

Description:

Positive lumpectomy margins are associated with an increased risk for ipsilateral tumor recurrence and necessitate additional procedures to achieve acceptable margins. Re-excision rates are higher in patients with ductal carcinoma in situ (DCIS) versus those with invasive carcinoma. The purpose of this program is to lead a discussion on the clinicopathologic characteristics, surgical techniques, and other outcomes associated with re-excision over time following primary breast conserving surgery.

Faculty:

• Freya R. Schnabel, MD
  Professor, Department of Surgery at NYU Grossman School of Medicine, Director of Breast Surgery NYU Langone

For More Information:

Contact Nancy King at nking@dilon.com.

Program Objectives:

• Review the wealth of data on the Oncotype DX Breast Recurrence Score® test in pre- and postmenopausal patients
• Interrogate current controversies at the intersection of genomic testing with patient menopausal status, local regional recurrence, and clinicopathologic features
• Discuss how guidelines have been informed by TAILORx and RxPONDER trials

Speakers:

• Tari King, MD, Chief, Breast Surgery, Dana Farber/Brigham and Women's Hospital
• Christy Russell, MD, Vice President, Medical Affairs, Exact Sciences
• Jennifer Racz, MD, Director, Medical Affairs, Oncology, Exact Sciences

For More Information:

Go to www.OncotypeIQ.com.

Overview:

See how surgeons around the world are using a single platform to achieve optimal clinical results while tailoring treatments for their patients. Enjoy hands-on experience with devices from biopsy to surgery and see what new technologies are on the horizon.

Faculty:

• Michael Alvarado, MD, University of California San Francisco
• Kandace P. McGuire, MD, Virginia Commonwealth University
• Eirini Pantiora, MD, Uppsala University Hospital, Sweden
• Rhiana Menen, MD, St. Luke's, Idaho

Agenda:

• Evidence-Based Decisions: What Will You Decide?
• Changing the Standard: The Evolution of Magtrace®
• Clinical Roundup: Thinking Global
• Ready, Set, Action! The Future of Magnetic Localization

For More Information:

Go to www.mammotome.com.

Overview

SCOUT® Radar localization exclusively spans the care continuum from time of biopsy placement to targeted axillary dissection to excellent surgical outcomes. Discover the state-of-the art localization techniques practiced by key opinion leaders from around the country. Learn how recent product innovations enable placing SCOUT under MRI guidance, future platform enhancements and the clinical and economic rationale for placing SCOUT at Time of Biopsy, providing a better patient experience, and streamlining workflow.

Overview

Welcome to the first installment of a 3-part series centered around the entire genetics and genomics landscape in breast cancer, covering patients at high risk, those who are newly diagnosed, undergoing treatment, or in survivorship. This series will equip you with the expertise to seamlessly integrate genetic and genomic testing into your clinical practice.

In part 1, we will delve into the foundations and applications of germline testing. Join us as we engage with experts in the field, including Jennifer Lazzara, DNP, ARNP, CGRA, who leads a Breast Cancer Genetics Clinic at Cancer Care Northwest, and Laura Brzeskiewicz, CGC, and Medical Science Liaison Manager at Myriad Genetics.

Overview:

Watch this informative webinar where subject matter experts in breast cancer review the various clinical applications of MRD testing using ctDNA testing to monitor high-risk patients. Learn more about the latest Signatera™ data in high-risk breast cancer:

Speakers:

• Dr. Minetta Liu, Chief Medical Officer, Natera Oncology
• Dr. Barry Rosen, Breast Surgical Oncologist, Advocate Good Shepard Hospital
• Dr. Angel Rodriguez, Breast Medical Oncologist, Medical Director, Natera Oncology

For More Information:

Please contact abet@natera.com.

Overview

View the replay of this educational session at the American Society of Breast Surgeons' 2023 Annual Meeting on how Perimeter’s margin visualization technology gives surgeons the real-time insights they need to personalize clinical decisions at the point of care.

Moderator:

• Susan Boolbol, MD

Panelists:

• Brigid Killelea, MD, FACS
• Michael Alvarado, MD
• Anne Peled, MD
• Lucy De La Cruz, MD

Description:

Not all seeds and tracers are created equal… join us as we take a deep-dive in to the technologies currently available for seed localization and axillary staging, alongside a world-class panel of breast surgical oncologists, with years of collective experience across all available seed localization devices on the market. The great localization debates will tackle everything from seed reliability to MRI visibility, metal instruments, accuracy of measurement, clinical efficacy, and much more.

That’s followed by the world-first, in-person launch of the next generation Sentimag® system and new Magseed® markers - built by Endomag, designed by you. Taking on board feedback from thousands of physicians worldwide, see how the new system has built on the strengths that have made Sentimag® so widely adopted, plus added an abundance of new advanced features.

Description:

PREVENT, the largest randomized clinical trial to assess lymphedema prevention, met its primary endpoint. Join our panel of experts as they debate the recently published results and implications for the future of breast cancer care. Topics covered will include the importance of early lymphedema detection and intervention, supporting clinical evidence, and real-world experience with clinical implementation. Discover how providing your patients with a lymphedema prevention program provides optimal patient care and can positively impact your practice.

Moderated By:

• Dr. Pat Whitworth
  Director
  Nashville Breast Center

Faculty:

• Dr. Beth DuPree
  Breast Surgeon
• Dr. Manpreet Kohli
  Breast Surgeon
  Breast Program Director Monmouth Medical Center
• Dr. Chirag Shah
  Co-Director Comprehensive Breast Program
  Director of Breast Cancer Radiation Oncology and Director of Clinical Research, Department of Radiation Oncology, Cleveland Clinic

Educational Objectives:

• Understand the latest evidence from the PREVENT trial
• Discover the benefits of identifying and treating lymphedema at the subclinical stage
• Learn the best practices and economics for implementing a lymphedema prevention program

Program Objective:

Go beyond wire-free localization into the advanced procedures of TAD and Delayed SLNB. Top experts from around the world review the latest data, the emerging procedures, and share their OR footage of their experiences. Get a glimpse of what’s on the horizon with the next generation Sentimag and dive into the ongoing research.

Agenda:

• The Latest Magseed® TAD Data
  Mr. Peter Barry, London’s Royal Marsden
• Delayed SLNB: The Future of Axillary Staging
  Kandace P. McGuire, MD - VCU
  Melissa Fana, MD - Northwell Health
• Magtrace Efficacy for SLNB Post-NAC
  Dr. Stefan Paepke, MD - Technical University of Munich
• SentiNOT 2.0 Trial and Recruitment Process
  Betsy Bonefas, MD – Baylor College of Medicine

Description:

SCOUT® Radar localization exclusively spans the care continuum from time of biopsy placement to Targeted Axillary Dissection to excellent surgical outcomes. Discover the state-of-the art localization and lymphatic mapping techniques practiced by key opinion leaders from the Cleveland Clinic and University of Colorado. Learn about upcoming SCOUT product enhancements and the clinical and economic rationale for placing SCOUT at Time of Biopsy.

Panelists:

• Brian Czerniecki, MD, PhD
• Colleen Murphy, MD, FACS
• Anne Peled, MD
• Stephanie Valente, DO, FACS

Description:

In this 30 minute clinical presentation, hear from Dr. Angel Rodriguez on how germline and somatic testing together can inform your surgical decisions, and identify more patients at high risk of cancer recurrence. This presentation will review the portfolio of Natera oncology solutions for germline and somatic testing including Signatera molecular residual disease (MRD) testing and Empower hereditary cancer testing (HCT).

For More Information:

Contact Wing-Kit Chu, Associate Director, Hereditary Cancer Marketing, at wichu@natera.com.

Program Objectives:

Upon completion of this CE activity, participants will be able to:

1. Describe DNA damage response (DDR) pathways and the rationale for therapeutic targeting of DDR with PARP inhibitors in early and advanced breast cancer
2. Identify patients with breast cancer who might benefit from treatment with PARP inhibitors based on current evidence and best practices for biomarker testing
3. Integrate PARP inhibitors into evidence-based, individualized treatment plans for eligible patients with early and advanced breast cancer considering latest efficacy and safety data in the context of clinical practice or clinical trials
4. Manage treatment-related adverse events in patients receiving PARP inhibitors for breast cancer treatment

Description:

Poly (ADP-ribose) polymerase (PARP) inhibition is now the standard of care for metastatic breast cancer harboring a germline BRCA1 or BRCA2 mutation, and studies continue to investigate PARP inhibitors as monotherapies or in rational combinations. Most recently, exciting results have revealed a potential role for PARP inhibitor therapy in earlier disease settings where there is a possibility for cure, heralding a new era of targeted therapy for patients with breast cancer. In order to maximize the benefits of these advances, it is crucial for the multidisciplinary breast cancer care team to keep current with the latest data and expert recommendations to effectively integrate PARP inhibitor therapy into clinical practice, as well as genetic counseling and biomarker testing to refine individualized therapy selection.

This PeerView Live Clinical Consults event for in-person and virtual attendees will provide essential information on the biologic rationale for targeting PARP, the latest data and their practical implications, guidance for optimizing biomarker testing, and strategies for improving multidisciplinary collaboration so that patients with breast cancer can make the most of the recent advances with PARP inhibitor therapy.

Accreditation, Support, and Credit:

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc.

Description:

Lumpectomy re-excisions remain a challenge for breast surgeons. Hear from Dr. Beth DuPree, an early OCT user, and Dr. Michele Carpenter, who described OCT as “like having a pathology slide in the OR.”

Speakers:

• Michele Carpenter, MD, FACS
  Breast Surgeon
  Orange, CA
• Beth DuPree, MD, FACS, ABOIM
  Breast Surgeon
  Sedona, AZ

For More Information:

Contact Linda Thomas, lthomas@perimetermed.com, 972‑672‑9700.

Featured Guests:

• Moderator: Dr. Richard Fine, Margaret West Comprehensive Breast Center, Memphis, TN
• Dr. Amelia Tower, Texas Health Breast Specialists, Fort Worth, TX
• Dr. Maryam Elmi, The START Center for Cancer Care, San Antonio, TX

Join us for an educational session on the intraoperative use of Perimeter’s groundbreaking margin visualization technology powered by Optical Coherence Tomography (OCT), bringing clarity to margin status at the point of care.

This presentation will cover:

• Technology behind Perimeter’s S-Series OCT, delivering high-resolution specimen imaging for intraoperative margin visualization
• OCT correlations with pathology
• Workflow for bringing OCT into your OR
• Lumpectomy case reviews, including recognizing suspicious tissues
• Bringing AI* to the operating room and investigational study updates
• Panel discussion and Q&A

*Perimeter is currently conducting a randomized control trial to assess its B-Series OCT imaging platform combined with AI technology on the impact of positive margin rates during breast conservation surgery. Perimeter B-Series OCT with ImgAssist AI is not available for sale in the United States. CAUTION: Investigational Device. Limited by U.S. law to investigational use.

Perimeter’s S-Series OCT is cleared by the FDA and available for sale in the U.S.

Overview:

During this live satellite symposium, a multidisciplinary panel of experts in the management of early-stage HR+/HER2- breast cancer will engage in a case-based discussion regarding the personalization of adjuvant therapy for these patients, particularly those with high-risk disease. Topics will include clinical and molecular factors for risk assessment, recent clinical data with endocrine regimens integrating CDK4/6 inhibitors, and management of adverse events associated with new agents. This program will highlight current best practices and the integration of emerging data into daily practice to optimize outcomes for patients with early-stage HR+/HER2- breast cancer, using a lively tumor-board format with opportunity for audience questions and interaction.

For help or questions please contact: info@gotoper.com.

Description:

Join us for a published data review of the highly anticipated DCISionRT validation results in the randomized SweDCIS patient cohort. Practicing physicians will be discussing implications of this new data and the clinical utility of DCISionRT in minimizing over- and under-treatment of DCIS patients. There will be interactive discussions about meaningful application of DCISionRT into surgical practice and real-world patient case studies regarding oncoplastic surgical planning.

Faculty:

• Anne Peled, MD
  Co-Director, Sutter CPMC Breast Cancer Program
• Karen Barbosa, DO, FACOS
  Breast Surgeon and Oncoplastic Surgeon and Medical Director, TidalHealth Delaware Breast Cancer Program
• Pat Whitworth, MD, FACS
  Breast Surgical Oncology Specialist, Director of the Nashville Breast Center
• Chirag Shah, MD
  Co-Director of the Comprehensive Breast Program, Cleveland Clinic
• Troy Bremer, PhD
  Founder and CSO of PreludeDx

For More Information:

Contact alindsay@preludedx.com, cdunn@preludedx.com